Ziccum CEO Analyst interview part 2

  • by

    • In part two of her Analyst interview CEO Ann Gidner offers a deep dive into the second of the company’s recent milestone Feasibility agreements plus an analysis of mRNA, why it is generating such historic levels of investment, and how Ziccum’s unique drying technology LaminarPace could be a key enabler in unlocking its potential.

    Watch Ziccum CEO Ann Gidner in the second part of her extended interview with Eucaps analyst Jonathan Furelid HERE.

    Or visit Ziccum’s company page on Eucaps HERE.

    For more information about Ziccum, please contact:

    Ann Gidner,
    CEO Ziccum
    Mail: gidner@ziccum.com
    Mobile: +46 722140141

    Fredrik Sjövall,
    Chairman of the Board, Ziccum AB
    Mail: sjovall@ziccum.com
    Mobile: +46 706 45 08 75
     
    Ziccum’s Certified Adviser is Erik Penser Bank AB
    Follow us on https://eucaps.com/ziccum

    About Ziccum

    Ziccum is developing LaminarPaceTM, a unique ambient drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPaceTM uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.

    Attachments

    Ziccum CEO Analyst interview part 2

    Ziccum CEO Analyst interview part 2